BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26917275)

  • 1. Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology.
    Jesinghaus M; Pfarr N; Endris V; Kloor M; Volckmar AL; Brandt R; Herpel E; Muckenhuber A; Lasitschka F; Schirmacher P; Penzel R; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Jun; 55(6):505-21. PubMed ID: 26917275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
    Magliacane G; Grassini G; Bartocci P; Francaviglia I; Dal Cin E; Barbieri G; Arrigoni G; Pecciarini L; Doglioni C; Cangi MG
    Oncotarget; 2015 Oct; 6(31):30592-603. PubMed ID: 26435479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
    Gailey MP; Stence AA; Jensen CS; Ma D
    Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
    Yanus GA; Belyaeva AV; Ivantsov AO; Kuligina ESh; Suspitsin EN; Mitiushkina NV; Aleksakhina SN; Iyevleva AG; Zaitseva OA; Yatsuk OS; Gorodnova TV; Strelkova TN; Efremova SA; Lepenchuk AY; Ochir-Garyaev AN; Paneyah MB; Matsko DE; Togo AV; Imyanitov EN
    Med Oncol; 2013; 30(3):686. PubMed ID: 23943423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
    Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I
    Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
    Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
    Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
    Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
    Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.
    Jesinghaus M; Pfarr N; Kloor M; Endris V; Tavernar L; Muckenhuber A; von Knebel Doeberitz M; Penzel R; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Mar; 55(3):268-77. PubMed ID: 26650777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.